Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Divestiture Remedies After FTC v. Sysco and Applied Materials/Tokyo Electron: Some Thoughts And Takeaways

Summary

Related Content

Antitrust Life Sciences Quarterly Update 2025 Q1

Antitrust & Competition Healthcare Quarterly Update Q1 2025

Practical Takeaways from the Recently Published EU Foreign Subsidies Decision in Case FS.100011 – e&/PPF

States Continue to Pursue and Expand Healthcare Market Oversight at an Unprecedented Pace, With Significant Implications for Private Equity

FTC’s First Merger Challenge Under New Leadership Signals Return to Traditional Antitrust Theories in Private Equity Deals

Antitrust and Competition Technology Year in Review 2024

Antitrust and Competition Life Sciences Year in Review 2024

How the Trump Administration Could Reshape Regulation in the Life Sciences Sector

Goodwin Named to Los Angeles Business Journal’s 2025 List of Largest Law Firms in LA

Vigil Neuroscience To Be Acquired by Sanofi For 470 Million and Contingent Value Rights

Goodwin Expands In Brussels With Antitrust Pro (Law360 UK)

Goodwin Bolsters Brussels Offering with Partner Athena Kontosakou and a Team of Global Antitrust and EU Regulatory Experts

Boston Forum: Merger Control & Competition in Life Sciences

Antitrust Considerations for the Pharmaceutical Industry: Pharmacy Benefit Managers (PBMs) and Algorithmic Pricing

ABA Antitrust Spring Meeting

Chambers Europe 2025 Recognizes Goodwin Across Belgium and the United Kingdom

Antitrust & Competition